# The Cytochrome CYP4 in Breast and Other Cancers

## TL;DR

This paper explores how CYP4 enzymes interact with estrogen receptors in breast cancer, suggesting new biomarkers and treatment possibilities.

## Contribution

The study identifies specific CYP4 genes correlated with breast cancer subtypes and estrogen receptor status, offering new therapeutic insights.

## Key findings

- CYP4B1 correlates with ESR1 in the basal subtype of breast cancer.
- CYP4F12 shows a significant positive correlation with BRCA1 in the Luminal B subtype.
- CYP4F3 correlates with BRCA1 and BRCA2 across multiple breast cancer subtypes.

## Abstract

The complex relationship between CYP enzymes and estrogen receptors in breast cancer is highlighted, revealing potential therapeutic interventions. The study reveals genomic alterations and differential expression patterns between normal and tumor tissues, suggesting a functional role in tumorigenesis. The positive correlation of these genes with estrogen receptor status strengthens their potential as predictive biomarkers.

Breast cancer has emerged as the leading cause of death among females worldwide. The CYPs play a crucial role in carcinogenesis. The role of the CYP enzyme family, particularly the CYP4 family, in cancer biology has attracted significant attention in recent years. Bioinformatics indicated that breast cancer is influenced by genes like CYP4B1, CYP4F12, and CYP4F3. CYP4B1 has a non-significant correlation with BRCA1 and BRCA2, but a positive correlation with ESR1 in the basal subtype. CYP4F12 has a significant positive correlation with BRCA1 in the Luminal B subtype, but not with BRCA2, and a positive correlation with ESR1 in the basal subtype. CYP4F3 has a significant positive correlation with BRCA1 in the Luminal A and Luminal B subtypes and with BRCA2 in Her2, Luminal A, and Luminal B subtypes, and a positive correlation with ESR1 in the basal subtype and Luminal B patients. This article aims to emphasize the functional importance of CYP4, highlighting the complex interplay between CYP enzymes and estrogen receptors in breast cancer, and indicating new avenues for future research and potential therapeutic interventions. In addition, their expression profiles and alterations were examined across various organs and cancer types. These findings underscore the potential relevance of these genes as predictive biomarkers and prospective therapeutic targets in specific cancer settings.